Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Mergers & acquisitions continue to change the medical device landscape, as reflected in Medical Design & Outsourcing’s new Big 100 list.
We pulled financial regulatory filings and reached out to major companies in some cases to create a list of the 100 largest medical device companies in the world, ranked by annual revenue for their medical device operations. Yesterday, we counted down Nos. 20–11. Today, it’s the top 10. Read more
As some companies have worked to improve drug-eluting stents by making them bioresorbable, some voices in the coronary intervention space have expressed concern over the rates of late stent thrombosis and repeat percutaneous coronary intervention seen with the devices.
In a study published in the September issue of JACC: Cardiovascular Intervention, Reva Medical‘s Fantom coronary bioresorbable vascular scaffold succeeded after six months. The device was designed to address challenges like strut size and expansion capacity, the researchers wrote. Read more
Abbott is facing an investor suit from an Alaskan union-benefits fund over allegations that St. Jude Medical, which it closed its acquisition of in January, failed to notify regulators about defective lithium batteries in its implantable defibrillators.
In the lawsuit, plaintiffs allege that St. Jude was informed of the battery defect “as early as 2011”, but it failed to take action and would wait 5 years before issuing a recall for the devices. Read more
Boston Scientific is reportedly still considering a market withdrawal in India for its Synergy adsorbable polymer stent, after repeated attempts to lift a government-imposed price cap were rebuffed by regulators there.
Representatives from the Marlborough, Mass.-based medical device giant met yesterday with National Pharmaceutical Pricing Authority officials to discuss pulling Synergy from India, according to LiveMint. The NPPA last week said no changes to the price caps would be considered until February 2018, a year after the caps went into effect, according to the website, which cited a ” person privy to the development.” Read more
Hurricane Maria is posing a threat to medical device and pharmaceutical manufacturing plants in Puerto Rico, according to a new Bloomberg report.
The island is home to facilities forJohnson & Johnson, Pfizer, Amgen, Merck, Medtronic, Abbott, Stryker and dozens of others, according to the report. Read more